{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:10:41Z","timestamp":1793725841509,"version":"4.6.1"},"reference-count":32,"publisher":"American Diabetes Association","issue":"4","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH","award":["2R01DK097554-06"],"award-info":[{"award-number":["2R01DK097554-06"]}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To examine the effect of empagliflozin on liver fat content in individuals with and without type 2 diabetes (T2D) and the relationship between the decrease in liver fat and other metabolic actions of empagliflozin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                    <jats:p>Thirty individuals with T2D and 27 without were randomly assigned to receive in double-blind fashion empagliflozin or matching placebo (2:1 ratio) for 12 weeks. Participants underwent 75-g oral glucose tolerance testing and measurement of liver fat content with MRS before therapy and at study end. Hepatic glucose production before the start of therapy was measured with 3-3H-glucose.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Empagliflozin caused an absolute reduction of 2.39% \u00b1 0.79% in liver fat content compared with an increase of 0.91% \u00b1 0.64% in participants receiving placebo (P &amp;lt; 0.007 with ANOVA). The decrease in liver fat was comparable in both individuals with diabetes and those without (2.75% \u00b1 0.81% and 1.93% \u00b1 0.78%, respectively; P = NS). The decrease in hepatic fat content caused by empagliflozin was strongly correlated with baseline liver fat content (r = \u22120.62; P &amp;lt; 0.001), decrease in body weight (r = 0.53; P &amp;lt; 0.001), and improvement in insulin sensitivity (r = \u22120.51; P &amp;lt; 0.001) but was not related to the decrease in fasting plasma glucose or HbA1c or the increase in hepatic glucose production.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Empagliflozin is effective in reducing liver fat content in individuals with and without T2D. The decrease in liver fat content is independent of the decrease in plasma glucose concentration and is strongly related to the decrease in body weight and improvement in insulin sensitivity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2337\/dc23-1646","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T16:58:00Z","timestamp":1706720280000},"page":"668-675","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":35,"title":["Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes"],"prefix":"10.2337","volume":"47","author":[{"given":"Siham","family":"Abdelgani","sequence":"first","affiliation":[{"name":"Division of Diabetes, University of Texas Health Science Center, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Khattab","sequence":"additional","affiliation":[{"name":"Division of Diabetes, University of Texas Health Science Center, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Adams","sequence":"additional","affiliation":[{"name":"Division of Diabetes, University of Texas Health Science Center, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gozde","family":"Baskoy","sequence":"additional","affiliation":[{"name":"Division of Diabetes, University of Texas Health Science Center, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Brown","sequence":"additional","affiliation":[{"name":"Division of Diabetes, University of Texas Health Science Center, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoff","family":"Clarke","sequence":"additional","affiliation":[{"name":"Division of Diabetes, University of Texas Health Science Center, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Larvenenko","sequence":"additional","affiliation":[{"name":"Division of Diabetes, University of Texas Health Science Center, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8581-6273","authenticated-orcid":false,"given":"Ralph A.","family":"DeFronzo","sequence":"additional","affiliation":[{"name":"Division of Diabetes, University of Texas Health Science Center, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4556-1787","authenticated-orcid":false,"given":"Muhammad","family":"Abdul-Ghani","sequence":"additional","affiliation":[{"name":"Division of Diabetes, University of Texas Health Science Center, San Antonio, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"2024032517503227600_B1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2024032517503227600_B2","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2468-1253(19)30419-4","article-title":"Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study","volume":"5","author":"Abeysekera","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2024032517503227600_B3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.metabol.2018.11.014","article-title":"Obesity and nonalcoholic fatty liver disease: from pathophysiology to therapeutics","volume":"92","author":"Polyzos","year":"2019","journal-title":"Metabolism"},{"key":"2024032517503227600_B4","doi-asserted-by":"crossref","first-page":"41518","DOI":"10.1038\/srep41518","article-title":"Six-year changes in the prevalence of obesity and obesity-related diseases in northeastern China from 2007 to 2013","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"key":"2024032517503227600_B5","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1007\/s00535-003-1178-8","article-title":"Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background","volume":"38","author":"Kojima","year":"2003","journal-title":"J Gastroenterol"},{"key":"2024032517503227600_B6","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/obr.12407","article-title":"Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies","volume":"17","author":"Li","year":"2016","journal-title":"Obes Rev"},{"key":"2024032517503227600_B7","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1053\/j.gastro.2020.01.051","article-title":"Therapeutic landscape for NAFLD in 2020","volume":"158","author":"Neuschwander-Tetri","year":"2020","journal-title":"Gastroenterology"},{"key":"2024032517503227600_B8","doi-asserted-by":"crossref","first-page":"e00163","DOI":"10.1002\/edm2.163","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (MASLD): a systematic review","volume":"3","author":"Lv","year":"2020","journal-title":"Endocrinol Diabetes Metab"},{"key":"2024032517503227600_B9","doi-asserted-by":"crossref","first-page":"615409","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis","volume":"12","author":"Lian","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2024032517503227600_B10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","article-title":"Role of sodium\u2013glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes","volume":"32","author":"Abdul-Ghani","year":"2011","journal-title":"Endocr Rev"},{"key":"2024032517503227600_B11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2024032517503227600_B12","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2024032517503227600_B13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"2024032517503227600_B14","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2024032517503227600_B15","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"key":"2024032517503227600_B16","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"key":"2024032517503227600_B17","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"2024032517503227600_B18","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"2024032517503227600_B19","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"2024032517503227600_B20","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2024032517503227600_B21","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","author":"Cusi","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2024032517503227600_B22","doi-asserted-by":"crossref","first-page":"978","DOI":"10.2337\/dc22-0885","article-title":"Distinct mechanisms responsible for the increase in glucose production and ketone formation caused by empagliflozin in T2DM patients","volume":"46","author":"Abdelgani","year":"2023","journal-title":"Diabetes Care"},{"key":"2024032517503227600_B23","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2337\/db19-0770","article-title":"Evidence against an important role of plasma insulin and glucagon concentrations in the increase in EGP caused by SGLT2 inhibitors","volume":"69","author":"Alatrach","year":"2020","journal-title":"Diabetes"},{"key":"2024032517503227600_B24","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1007\/s00125-020-05254-w","article-title":"Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy","volume":"63","author":"Daniele","year":"2020","journal-title":"Diabetologia"},{"key":"2024032517503227600_B25","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/dom.14650","article-title":"Combination therapy with pioglitazone\/exenatide\/metformin reduces the prevalence of hepatic fibrosis and steatosis: the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT)","volume":"24","author":"Lavynenko","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"2024032517503227600_B26","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.2337\/diacare.22.9.1462","article-title":"Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp","volume":"22","author":"Matsuda","year":"1999","journal-title":"Diabetes Care"},{"key":"2024032517503227600_B27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J Clin Invest"},{"key":"2024032517503227600_B28","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/hep4.1696","article-title":"Ipragliflozin improves the hepatic outcomes of patients with diabetes with MASLD","volume":"6","author":"Takahashi","year":"2022","journal-title":"Hepatol Commun"},{"key":"2024032517503227600_B29","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N Engl J Med"},{"key":"2024032517503227600_B30","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2337\/dc15-2688","article-title":"Dapagliflozin enhances fat oxidation and ketone production in patients with type 2 diabetes","volume":"39","author":"Daniele","year":"2016","journal-title":"Diabetes Care"},{"key":"2024032517503227600_B31","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2337\/db19-1152","article-title":"Adaptation of insulin clearance to metabolic demand is a key determinant of glucose tolerance","volume":"70","author":"Gastaldelli","year":"2021","journal-title":"Diabetes"},{"key":"2024032517503227600_B32","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.2337\/db17-0413","article-title":"Hepatic but not extrahepatic insulin clearance is lower in African American than in European American women","volume":"66","author":"Piccinini","year":"2017","journal-title":"Diabetes"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/47\/4\/668\/751704\/dc231646.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/47\/4\/668\/751704\/dc231646.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T13:51:14Z","timestamp":1711374674000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/47\/4\/668\/154175\/Empagliflozin-Reduces-Liver-Fat-in-Individuals"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":32,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,1,31]]},"published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc23-1646","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]}}}